WO2008007450A1 - Aliment, boisson et composition médicinale ayant un effet antitumoral - Google Patents

Aliment, boisson et composition médicinale ayant un effet antitumoral Download PDF

Info

Publication number
WO2008007450A1
WO2008007450A1 PCT/JP2006/322571 JP2006322571W WO2008007450A1 WO 2008007450 A1 WO2008007450 A1 WO 2008007450A1 JP 2006322571 W JP2006322571 W JP 2006322571W WO 2008007450 A1 WO2008007450 A1 WO 2008007450A1
Authority
WO
WIPO (PCT)
Prior art keywords
extract
tumor
feverfew
food
drink
Prior art date
Application number
PCT/JP2006/322571
Other languages
English (en)
Japanese (ja)
Inventor
Osamu Masaki
Chieko Asamori
Original Assignee
Mmt Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mmt Co., Ltd. filed Critical Mmt Co., Ltd.
Priority to JP2006549204A priority Critical patent/JPWO2008007450A1/ja
Publication of WO2008007450A1 publication Critical patent/WO2008007450A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the present invention relates to foods and drinks and pharmaceutical compositions having a tumor-suppressing action, and methods for suppressing tumors.
  • a food and drink and a pharmaceutical composition containing an extract of an Asteraceae plant, and a method for suppressing a tumor characterized by administering an extract of an Asteraceae plant to a patient, and a method for suppressing the tumor The present invention relates to the use of asteraceae extracts in the manufacture of pharmaceutical compositions.
  • Tumors are considered to be one of the most difficult diseases to treat, and various studies have been conducted on the treatment, new therapies and drugs have been developed, and treatment results have been improved. However, many of these therapies and drugs are burdensome to patients and have significant side effects. In particular, metastatic tumors are difficult to treat, and many studies have been made (see Non-Patent Document 1, etc.). Recently, as a cancer treatment that is kind to the body, treatment using immune cell therapy and Chinese medicine, or health foods derived from mushroom extracts and plant extracts, etc. have been developed. ing.
  • the problem to be solved by the present invention is to provide a treatment for tumors that is effective and superior in strength to patients.
  • food and drink and pharmaceutical composition comprising an extract of a asteraceae plant, in particular feverfew, which exhibits a remarkable tumor-suppressing effect upon ingestion and is highly safe. Things are provided. Furthermore, a method for suppressing a tumor characterized by administering an extract of Asteraceae plant, specifically feverfew to a patient, and a medicinal plant in manufacturing a pharmaceutical composition for suppressing a tumor, more specifically feverfew Use of the extract is also provided. Therefore, an effective, body-friendly, tumor suppressor treatment is provided.
  • the present invention provides the following:
  • a pharmaceutical composition for suppressing a tumor comprising an extract of a asteraceae plant
  • a method for suppressing a tumor which comprises feeding on an extract of an Asteraceae plant
  • a method for suppressing a tumor in a patient comprising administering an extract of a asteraceae plant to the patient;
  • FIG. 1 is a graph showing the time course of survival rate when a feverfew extract or parthenolide is administered to tumor mice.
  • the solid line is the vehicle control group
  • the dashed line is the nortenolide 40 mg ZkgZ daily oral administration group
  • the dashed line is the feverfew extract 222 mg ZkgZ oral oral administration group.
  • the feverfew extract 222 mg ZkgZ day-treated group showed a significant difference from the vehicle control group (P 0.05, Log-Rank test).
  • FIG. 2 is a graph showing the results of observing the size of the tumor primary lesion over time.
  • the black circles are the vehicle control group, the white squares are the baltenolide 40 mg ZkgZ oral administration group, and the black triangles are the feverfew extract 222 mg ZkgZ oral administration group.
  • Vertical bars indicate standard deviation
  • FIG. 3 is a graph showing the change in body weight over time when feverfew extract or cisbratine is administered to tumor mice.
  • the black circle is the vehicle control group
  • the white square is the feverfew extract 222 mgZkgZ daily oral administration group
  • the black square is the feverfew extract 888 mgZkgZ daily oral administration group
  • the white triangle is the cisplatin lOmgZkgZ day intraperitoneal administration group.
  • FIG. 4 is a graph showing the time course of survival rate when feverfew extract or cisbratine is administered to tumor mice.
  • the solid line is the vehicle control group
  • the dashed line is the feverfew extract 222 mgZkgZ daily oral administration group
  • the broken line is the feverfew extract 888 mgZ kg / day oral administration group
  • the dotted line is the cisplatin lOmgZkgZ day intraperitoneal administration group.
  • the feverfew extract 888mgZkgZ day group showed a significant difference from the vehicle control group (p ⁇ 0.05, Log-Rank test).
  • the present invention relates to a food and drink for suppressing tumors, which contains an extract of a plant containing sesquiterpene ratatones.
  • to suppress tumor is to treat tumor It includes prevention as well.
  • the plant extract used in the food and drink of the present invention is not particularly limited as long as it is a plant extract containing sesquiterbene lactones.
  • Examples of plants containing a large amount of sesquiterpene ratatones include asteraceae plants, such as plants of the genus Artemisia and dandelions. Therefore, in one aspect, the present invention provides a food and drink for suppressing tumors, which contains an extract of a asteraceae plant.
  • parthenolide has been reported to have various physiological activities so far, and as shown in Japanese Patent Application Laid-Open No. 2005-35951, it suppresses tumor metastasis and exerts an animal life-prolonging effect. It has been shown. Therefore, it is preferable to use plants with a high content of valthenolide.
  • plants include asteraceae plants, preferably plants belonging to the genus Artemisia, particularly preferably Tanacetum parthenium (also referred to as fever-fu).
  • a particularly preferred plant extract for use in the present invention is feverfew extract.
  • parthenolide when feverfew extract is orally administered to animals, only a very small amount of parthenolide is administered in terms of parthenolide, but even in this case, a tumor suppression effect superior to that of bartenolide alone is obtained. (See Examples).
  • Plant extracts can be obtained by general methods.
  • the extraction site may be any site as long as it is an aerial part of the plant, but in the case of an Asteraceae plant such as feverfew, a preferable extraction site is a leaf.
  • the extract may be obtained by immersing the plant in a solvent as it is, but the extraction efficiency is higher when the contents are extracted by crushing the force.
  • Plants may be raw or dried. For drying, a known drying method such as warm air drying or air drying can be used. Various plant crushing means can be used.
  • Suspension / extraction media include ether, methanol, ethanol, or a mixture of ethanol and water. Suspension media should be less toxic Those that are non-toxic or non-toxic are preferred. From this viewpoint, ethanol or a mixture of ethanol and water is particularly preferable as a suspension / extraction medium.
  • Extraction conditions such as temperature and time during suspension 'extraction can be selected according to the type and amount of plants. Usually, it is extracted at room temperature and normal pressure for several hours to several days.
  • the above-ground parts of plants, such as leaves and stems are directly dried by a known drying method such as hot air drying or air drying, and pulverized to obtain a food or drink or pharmaceutical of the present invention. May be used in the composition
  • the obtained extract is subjected to a known method such as decantation, filtration, or centrifugation to obtain a solid content and a particulate matter. Can be removed.
  • the obtained extract may be concentrated by a known method such as evaporation.
  • the obtained extract may be dried by a known method to obtain a solid such as a powder.
  • the obtained extract may be further purified and used by known methods such as various chromatography and precipitation methods.
  • the plant extract used in the food and drink according to the present invention can be obtained as described above. These extracts can be made into various forms using known methods according to the use form and purpose, and prepared into liquid, semi-solid, solid (for example, powder such as freeze-dried powder), etc. Can do.
  • An Asteraceae plant extract can be blended with various foods to obtain the foods and drinks of the present invention.
  • These asteraceae plant extracts are of low toxicity or non-toxic because they are derived from natural products, and can be incorporated into any food or drink.
  • the extract may be blended with juice or a noove seasoning.
  • the food and drink of the present invention can be a health food, a functional nutritional food, or a food for specified health use (so-called “tokuho”).
  • supplements are mentioned as a preferred form of the food and drink of the present invention.
  • the supplement may be in any shape that can be taken orally, such as tablets, capsules, granules, and powders (e.g., freeze-dried powder). Etc.), suspensions, drinks, elixirs, possible forms, jelly forms and the like.
  • These supplements are used in the food and pharmaceutical fields.
  • a general process such as mixing and encapsulation can be used.
  • Soft capsules and hard capsules can also be appropriately selected according to the purpose.
  • the extract can be dissolved or suspended in a less toxic medium such as ethanol.
  • a less toxic medium such as ethanol.
  • the usual processes such as mixing, drying, grinding and sieving can also be used.
  • a carrier or excipient is used in the production of supplements, the type and amount can be selected according to the practice in the pharmaceutical field.
  • solid carriers or excipients include talc, carboxymethylcellulose, sucrose, and wheat flour.
  • the liquid carrier include water, ethanol, and edible fats and oils.
  • the food and drink of the present invention is effective in suppressing all tumors. Since sesquiterpene ratatones are contained in the plant extract of the present invention, as in JP-A-2005-35951, the food and drink of the present invention is also effective for tumor suppression, particularly tumor metastasis suppression. To promote the survival of animals.
  • Asteraceae extract per day depends on the amount of sesquiterbene lactones, especially nortenolide contained. In the case of feverfew extract, it is common to take about 0.05g to 50g per day for adults (weight 70kg), and it is appropriate to eat or eat about 0.15g to 15g. is there.
  • the food and drink or supplement of the present invention not only asteraceae plant extracts but also one or more other active ingredients may be mixed.
  • chemotherapy such as antitumor agents (eg, fluorouracil, bleomycin, paclitaxel, cisplatin), hormone agents (eg, tamoxifen, phosfestol), immunostimulants (eg, arabinoxylan, chitosan, esukoggi), etc.
  • the agent and the food and drink of the present invention may be used in combination.
  • a person who has already undergone treatment such as chemotherapy, surgery, radiation therapy, hormone therapy, and immunotherapy can promote the therapeutic effect by eating the food or drink of the present invention.
  • the dose of the drug can be reduced, and treatment can be realized with ease for the patient.
  • the food and drink of the present invention includes not only human but also non-human animal feed.
  • the present invention provides a pharmaceutical composition for tumor suppression comprising an Asteraceae extract, preferably a feverfew extract.
  • the active ingredient in the pharmaceutical composition of the present invention is the above-mentioned Asteraceae plant extract, preferably feverfew extract.
  • a product obtained by purifying these extracts and increasing the content of barthenolide may be used.
  • the pharmaceutical composition of the present invention can be formulated into various dosage forms.
  • the pharmaceutical composition of the present invention is preferably in a dosage form suitable for oral administration.
  • a dosage form suitable for oral administration For example, tablets, capsules, granules , Powder, drinks and so on.
  • sesquiterpene ratatones such as parthenolide are used as the active ingredient
  • the pharmaceutical composition of the present invention is preferably in a dosage form suitable for oral administration and topical administration, but administration by other administration routes. Is also possible.
  • These dosage forms can be produced by methods known in the pharmaceutical field.
  • the pharmaceutical composition of the present invention is effective in suppressing any tumor.
  • the pharmaceutical composition of the present invention also contains tumor suppression, particularly in the case where sesquiterpene ratatones are contained in the plant extract of the present invention! It is effective in suppressing tumor metastasis and promotes the survival of animals.
  • the active ingredient in the pharmaceutical composition of the present invention is an Asteraceae plant extract, taking a feverfew extract as an example, the daily dose is 0 per day for an adult (body weight 70 kg). About 05g to 5Og is common, and about 0.15g to 15g is appropriate. These dosages can be changed as appropriate by the doctor according to the patient's symptoms, disease site, sex, age, weight, presence of side effects, and other factors such as treatment being received.
  • the pharmaceutical composition of the present invention not only asteraceae plant extracts and parthenolides, but also one or more other active ingredients may be mixed.
  • chemotherapy such as antitumor agents (for example, fluorouracil, bleomycin, paclitaxel, cisplatin), hormone agents (for example, tamoxifen, phosfestol), immunostimulants (for example, alapinoxylan, chitosan, ezoukogi, etc.)
  • An agent and the pharmaceutical composition of the present invention may be used in combination.
  • a person receiving treatment such as therapy to promote the therapeutic effect by administering the pharmaceutical composition of the present invention.
  • the pharmaceutical composition of the present invention is used in combination, the dose of the drug can be reduced, and the patient can be treated with superior therapy.
  • the pharmaceutical composition of the present invention includes not only a human but also a non-human animal pharmaceutical composition such as a veterinary pharmaceutical composition.
  • the present invention relates to a method for inhibiting a tumor, characterized by feeding on an extract of an Asteraceae plant. Eating means eating and drinking from the mouth. Normally, the extracts of Asteraceae plants are provided in the form of food and drink, but may be provided in the form of supplements. The form of food and drink and supplements are as described above.
  • a preferable extract of the Asteraceae plant in the above method is a feverfew extract.
  • the tumor suppressed by the above method is a metastatic tumor.
  • the present invention relates to a method for suppressing a tumor in a patient, characterized by administering an extract of an Asteraceae plant to the patient.
  • An extract of the Asteraceae plant may be given to the patient as it is, but is preferably given to the patient in the form of a pharmaceutical composition.
  • the dosage form and route of administration of the pharmaceutical composition are as described above for the pharmaceutical composition of the present invention.
  • a preferable extract of the Asteraceae plant is a feverfew extract.
  • the tumor suppressed by the above method is a metastatic tumor.
  • the present invention provides the use of an extract of a asteraceae plant in the manufacture of food and drink for tumor suppression.
  • the food and drink may be in the form of a supplement.
  • the form of food and drink and supplements are as described above.
  • a preferable extract of the Asteraceae plant in the above use is a feverfew extract.
  • the tumor suppressed by the use is a metastatic tumor.
  • the present invention provides the use of an extract of Asteraceae in the manufacture of a pharmaceutical composition for tumor suppression.
  • the form of the pharmaceutical composition produced by this use, the route of administration, and the amount of Asteraceae extract to be administered are as described above.
  • a preferred extract of the Asteraceae plant in the above use is feverfew extract.
  • the tumor suppressed by the use is a metastatic tumor.
  • tumor suppression includes prevention, prevention or suppression of tumor development, suppression or termination of tumor development, and suppression or elimination of tumor metastasis.
  • Example 1 Effect of feverfew extract and parthenolide on the survival rate of tumor mice
  • Feverfew Extract (batch number: 051016-107) manufactured by HANDA FINE CHEMICALS was used as the feverfew extract. The content of parthenolide in this extract was about 0.9%. Parthenolide manufactured by sigma (purity of 90% or more) was used. The feverfew extract was dissolved in a 0.5 wZv% aqueous solution of methylcellulose and orally administered to the animals using a metal sonde (once a day, administration volume lOmLZkgZ). Feverfew extract The dose was 222 mgZkgZ day, and the dose of parthenolide was 40 mgZkgZ day. The vehicle control group received 0.5 wZv% methylcellulose aqueous solution. The number of animals per experiment was 10.
  • the animal used was a male C3H / HeN Sic mouse (Sankyo Lab Service Co., Ltd.), which was conditioned at 3 weeks of age and weighing 9-14 g, and used at 4 weeks of age. During the experiment period, animals were given solid feed MF (Oriental Yeast Co., Ltd.) and filter-sterilized tap water freely.
  • a tumor model was prepared as follows.
  • a tumor model was prepared by subcutaneously injecting 5 lxlO (in 100 L) mouse tumor cells (LM8 cells of an osteosarcoma cell line) into the back of a 4-week-old mouse that had undergone intensive hair removal. After preparing the tumor model, feverfew extract and vehicle were orally administered once a day for 8 weeks, and the survival rate was calculated.
  • Figure 1 shows the experimental results. Life-survival effect was observed in the feverfew extract-administered group, especially in the feverfew extract 222 mgZkgZ day-administered group. The survival rate was about 0.1, whereas the survival rate of the feverfew extract 222 mg ZkgZ day administration group was about 0.45).
  • the dose of feverfew extract 222 mgZkgZ days corresponds to parthenolide 2.0 mg / kg / day. It is surprising that a high tumor suppressive effect was obtained when the extract was administered orally. The reason may be a synergistic effect of other components contained in the feverfew extract. In addition, the essential oil components in the extract are considered to have worked well.
  • the safety of the feverfew extract used in the above experiments was investigated.
  • the test method was the OECD chemical test guideline (TG420) fixed dose method, and Sic: ICR female mice were used.
  • TG420 OECD chemical test guideline
  • Sic ICR female mice were used.
  • the LD value of pear extract was evaluated to be 2000 mgZkg or more.
  • the mutagenicity of feverfew extract used in the above experiment was determined using Salmonell as a test bacterium. atyphimurium TA100, TA1535, TA98, TA1537 and Escherichia coli WP2 uvrA were used in the absence and presence of S9mix. As a result, the mutagenicity was not observed even at the dose of 5000 gZ plate. From these results, it was proved that feverfew extract is extremely safe and safe.
  • the feverfew extract and parthenolide were the same as in Example 1.
  • the method of administration to animals was also the same as in Example 1.
  • the doses were feverfew extract 222 mgZkgZ day and parthenolide 40 mg / kg / day, and 0.5 w / v% methylcellulose aqueous solution was orally administered to the vehicle control group.
  • mice Os C3H / HeN Sic mice (Sankyo Lab Service Co., Ltd.), which were used for experiments at the age of 3 weeks and acclimated to those with body weights of 10.3 to 13.6 g. did.
  • animals were freely given solid feed MF (Oriental Yeast Co., Ltd.) and filter-sterilized tap water.
  • a tumor model was prepared as follows.
  • a tumor model was prepared by subcutaneously injecting 5 lxlO (in 100 L) mouse tumor cells (LM8 cells of an osteosarcoma cell line) into the back of a 5 week-old mouse that had been brutally removed.
  • 5 lxlO in 100 L
  • mouse tumor cells LM8 cells of an osteosarcoma cell line
  • the feverfew extract, nortenolide and vehicle are orally administered once a day, and at the time when death occurred and transfer to the lung was observed (treatment initiation force was also on the 34th day)
  • Primary tumors, lungs and liver were removed and embedded in paraffin.
  • Lung specimens are sliced horizontally at the center of the left lobe, stained with hematoxylin 'eosin (HE), photographed under a microscope, photographed into a computer, and image analysis software (Image Tool ver .3.00, UTHSCSA) was used to determine the lung area and metastasis area, and the ratio (%) of the metastasis area to the lung area was calculated.
  • HE hematoxylin 'eosin
  • Vehicle control 101 248024 1154618 21. 48 c. / Retenolite, '
  • the feverfew extract and parthenolide were the same as in Examples 1 and 2.
  • the method of administration to animals was also the same as in Examples 1 and 2.
  • the dosage was feverfew extract 222 mg / kg / day, parthenolide 40 mg ZkgZ day, and the vehicle control group was given 0.5 w / v% methylcellulose aqueous solution.
  • the animals used were the same as in Example 2, and 8 animals were used per group.
  • the animal used was a male C3H / HeN Sic mouse (Sankyo Lab Service Co., Ltd.), which was conditioned at 3 weeks of age and weighing 10 to 14 g and used in the experiment at 5 weeks of age. During the experiment period, animals were given solid feed MF (Oriental Yeast Co., Ltd.) and filter-sterilized tap water freely.
  • the tumor model was prepared in the same manner as in Example 2. After the tumor model was created, feverfew extract, nortenolide and vehicle were orally administered once a day, and the tumor size (major axis and minor axis) was changed three times a week from 2 weeks to the 33rd day after tumor cell transplantation. Vernier caliper (CD-I The tumor volume was calculated using 5PS, Mitutoyo). The volume was assumed to be an ellipsoidal sphere and was calculated using the following formula:
  • Tumor volume 4 ⁇ 3 ⁇ (minor axis Z2xminor axis Z2xmajor axis Z2)
  • Figure 2 shows the experimental results.
  • the increase in the primary tumor volume was most suppressed, and a marked effect began to appear around day 26. About 40% of the nest tumor volume.
  • the group treated with nortenolide 40 mg ZkgZ no significant difference was observed from the vehicle control group. If the content of nortenolide in the feverfew extract is 0.9%, the dose of feverfew extract 222 mg / kg / day corresponds to the date of barthenolide 2. OmgZkgZ. In this experiment as well, it was found that when the extract was orally administered, a significant primary volume reduction effect was obtained.
  • Example 4 Comparison of body weight change in feverfew extract administration group and body weight change in cisbratine administration group
  • Feverfew Extract (batch number: 051016-107) manufactured by HANDA FINE CHEMICALS was used as the feverfew extract.
  • the content of parthenolide in this extract was about 0.9%.
  • the feverfew extract was dissolved in 0.5 wZv% methylcellulose aqueous solution and orally administered to the animals using a metal sonde (once daily, administration volume lOmLZkgZ times).
  • the dosage of feverfew extract was 222 mgZkgZ days and 888 mgZkgZ days.
  • cisplatin 0.5 mg / ml injection was administered after calculating the necessary amount based on the body weight of the animals.
  • the cisbratin dose was lOmgZkg, and intraperitoneal injection was performed using an injection needle (26G, manufactured by Terumo Corporation) and a syringe (1 mL capacity, manufactured by Terumone Soil).
  • the vehicle control group was orally administered with 0.5 wZv% methylcellulose aqueous solution.
  • the number of animals per experiment was 10.
  • the animals used were Os C3H / HeN Sic mice (Sankyo Lab Service Co., Ltd.), which were used for experiments at the age of 3 weeks and acclimated to weights from 9.9 to 13.8 g. did. Animals during the experiment Solid feed MF (manufactured by Oriental Yeast Co., Ltd.) and filter-sterilized tap water were freely given.
  • a tumor model was prepared as follows.
  • a tumor model was prepared by subcutaneously injecting 5 lxlO (in 100 L) mouse tumor cells (LM8 cells of an osteosarcoma cell line) into the back of a 4-week-old mouse that had undergone intensive hair removal. After the tumor model was created, feverfew extract and vehicle were orally administered once a day for a maximum of 6 weeks, and the weight of each animal was measured to calculate the survival rate. Cisbratin was administered intraperitoneally one week after the tumor model was prepared.
  • Figure 3 shows the experimental results.
  • weight loss was observed after the 6th day of administration compared to the control group, and this tendency continued until the end of the experimental period.
  • feverfew extract 888 mgZkg and 222 mgZkg groups there was no significant decrease in body weight compared to the control group.
  • Example 5 Ratio of survival rate of feverfew extract administration group to survival rate of cisbratine administration group
  • Figure 4 shows the experimental results.
  • the feverfew extract 888 mgZkg group there was no significant decrease in survival rate over 42 days.
  • the decrease in survival rate was well suppressed, and the survival rate on day 42 was 0.7.
  • the survival rate in the splatin group was 0.4 on day 40 (same as the control group at this point), and the survival rate was lower than that in the feverfew extract group.
  • feverfew extract has been shown to extremely effectively suppress the decrease in the survival rate of tumor animals. Considering the toxicity and side effects of cisbratine, administer a large amount for tumor suppression effect equivalent to or better than feverfew extract I can't. However, cisbratine is expensive. On the other hand, as shown in Example 4, feverfew extract is highly safe and has an excellent tumor suppression effect. Moreover, feverfew extract exhibits an excellent tumor suppressive effect when administered orally. In addition, feverfew extract is much cheaper than anticancer drugs such as cisbratine. Considering these points, feverfew extract is considered to have excellent effects and usefulness that are not found in conventional anticancer agents!
  • the present invention is useful in the fields of health foods and pharmaceuticals.

Abstract

L'invention concerne un aliment, une boisson et une composition médicinale contenant un extrait d'une plante astéracée, plus précisément de grande camomille (Tanacetum parthenium), lequel présente un effet antitumoral remarquable lorsqu'il est absorbé par voie orale. De plus, l'invention concerne un procédé d'inhibition d'une tumeur caractérisé en ce qu'il consiste à administrer un extrait d'une plante astéracée, plus précisément de grande camomille (Tanacetum parthenium), à un patient ; l'utilisation d'un extrait d'une plante astéracée, plus précisément de grande camomille (Tanacetum parthenium), dans la production d'une composition médicinale servant à inhiber une tumeur ; entre autres.
PCT/JP2006/322571 2006-07-14 2006-11-13 Aliment, boisson et composition médicinale ayant un effet antitumoral WO2008007450A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2006549204A JPWO2008007450A1 (ja) 2006-07-14 2006-11-13 腫瘍抑制作用を有する飲食物および医薬組成物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006-194119 2006-07-14
JP2006194119 2006-07-14

Publications (1)

Publication Number Publication Date
WO2008007450A1 true WO2008007450A1 (fr) 2008-01-17

Family

ID=38923023

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2006/322571 WO2008007450A1 (fr) 2006-07-14 2006-11-13 Aliment, boisson et composition médicinale ayant un effet antitumoral

Country Status (2)

Country Link
JP (1) JPWO2008007450A1 (fr)
WO (1) WO2008007450A1 (fr)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001045699A1 (fr) * 1999-12-23 2001-06-28 Advanced Research And Technology Institute, Inc. Utilisation du parthenolide pour inhiber le cancer
WO2002040017A1 (fr) * 2000-11-15 2002-05-23 National University Of Singapore Agent chimiotherapeutique et de chimio-prevention du cancer
JP2002518456A (ja) * 1998-06-25 2002-06-25 カート・ヘンドリクス 脳血管の正常状態を支持するための栄養補助食品
WO2004093518A2 (fr) * 2003-04-16 2004-11-04 The University Of Mississippi Agents immunostimulateurs presents dans des produits phytopharmaceutiques
JP2004352626A (ja) * 2003-05-28 2004-12-16 Asahi Breweries Ltd 植物由来成分を含有する抗コレステロール剤
JP2005035951A (ja) * 2003-07-17 2005-02-10 Akira Nai 腫瘍転移抑制剤
JP2005538161A (ja) * 2002-09-09 2005-12-15 ジョンソン・アンド・ジョンソン・コンシューマー・カンパニーズ・インコーポレイテッド ナツシロギクエキスを含有する組成物及びそれの使用方法

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002518456A (ja) * 1998-06-25 2002-06-25 カート・ヘンドリクス 脳血管の正常状態を支持するための栄養補助食品
WO2001045699A1 (fr) * 1999-12-23 2001-06-28 Advanced Research And Technology Institute, Inc. Utilisation du parthenolide pour inhiber le cancer
WO2002040017A1 (fr) * 2000-11-15 2002-05-23 National University Of Singapore Agent chimiotherapeutique et de chimio-prevention du cancer
JP2005538161A (ja) * 2002-09-09 2005-12-15 ジョンソン・アンド・ジョンソン・コンシューマー・カンパニーズ・インコーポレイテッド ナツシロギクエキスを含有する組成物及びそれの使用方法
WO2004093518A2 (fr) * 2003-04-16 2004-11-04 The University Of Mississippi Agents immunostimulateurs presents dans des produits phytopharmaceutiques
JP2004352626A (ja) * 2003-05-28 2004-12-16 Asahi Breweries Ltd 植物由来成分を含有する抗コレステロール剤
JP2005035951A (ja) * 2003-07-17 2005-02-10 Akira Nai 腫瘍転移抑制剤

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CALTAGIRONE S. ET AL.: "Flavonoids apigenin and quercetin inhibits melanoma growth and metastatic potential", INT. J. CANCER, vol. 87, no. 4, 2000, pages 595 - 600, XP003020508 *
WU C. ET AL.: "Antiproliferative Activities of Parthenolide and Golden Feverfew Extract Against Three Human Cancer Cell Lines", JOURNAL OF MEDICINAL FOOD, vol. 9, no. 1, March 2006 (2006-03-01), pages 55 - 61, XP003020507 *

Also Published As

Publication number Publication date
JPWO2008007450A1 (ja) 2009-12-10

Similar Documents

Publication Publication Date Title
JP2008542300A (ja) 炎症と関連した状態を予防及び治療するための組成物及び方法
WO2006033412A1 (fr) Médicament soulageant les troubles dus aux radiations
JP3988168B1 (ja) イチョウ葉エキスナノ微粒子による脳細胞活性効果を有する組成物
US20180353540A1 (en) Pharmaceutical composition for treating leukemia and preparation method thereof
WO2004112773A1 (fr) Compositions pharmaceutiques utilisees pour le traitement de maladie immune et amelioration
CN107569608B (zh) 一种用于降血糖的药物组合物
JP2007055929A (ja) 肝保護剤組成物
KR101731859B1 (ko) 진피 추출물을 포함하는 이상 체중 감소 증상의 예방 또는 치료용 조성물
KR101989739B1 (ko) 구슬갓냉이 추출물을 유효성분으로 포함하는 당뇨병의 예방 또는 치료용 조성물
WO2008010335A1 (fr) Extrait végétal ayant un effet préventif sur l'arthrite
WO2014134833A1 (fr) Composition comestible, son procédé de préparation, et produit alimentaire comprenant la composition
KR101898891B1 (ko) 진세노사이드 화합물 k를 이용한 세포독성 항암제 부작용 억제용 조성물
KR101528557B1 (ko) 천년초 발효물 함유 의약 조성물
WO2011095095A1 (fr) Composition médicinale comprenant un extrait de réglisse soluble dans les alcools et insoluble dans l'eau et préparation pharmaceutique, application pharmaceutique, procédé thérapeutique et procédé de préparation correspondants.
WO2008007450A1 (fr) Aliment, boisson et composition médicinale ayant un effet antitumoral
JP2016108265A (ja) 持続性抗酸化剤
JP2016537428A (ja) エフェドラ・アラタ抽出物及びその使用方法
CN112353837B (zh) 葛花提取物及其用途
WO2008075649A1 (fr) Boisson, aliment, alicament, composition médicinale et procédé destinés à favoriser la croissance capillaire
CN102125646B (zh) 一种中药组合物在治疗胃部慢性炎症伴肠上皮化生、上皮内瘤变的应用
JP4681246B2 (ja) 免疫賦活剤
JP2003286181A (ja) アトピー性皮膚炎易発症体質改善剤
JPH02279629A (ja) 肺癌に適応性を有する抗腫瘍剤
Kemper Shark cartilage, cat's claw, and other complementary cancer therapies
JP2004115420A (ja) 気管支及び肺疾患の治療剤及びそれを含有する飲食品

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2006549204

Country of ref document: JP

Kind code of ref document: A

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06823345

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06823345

Country of ref document: EP

Kind code of ref document: A1